Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Upgraded at ValuEngine
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
A number of other equities research analysts have also recently issued reports on DRNA. Zacks Investment Research cut Dicerna Pharmaceuticals from a buy rating to a hold rating in a report on Friday, March 24th. Cowen and Company restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 9th. HC Wainwright reiterated a buy rating and issued a $5.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 23rd. Finally, Jefferies Group LLC reiterated a buy rating and issued a $7.00 price target (down from $8.00) on shares of Dicerna Pharmaceuticals in a research note on Sunday, April 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of Hold and an average target price of $6.35.
Dicerna Pharmaceuticals (NASDAQ DRNA) traded down 4.91% during midday trading on Friday, reaching $3.10. The company’s stock had a trading volume of 146,189 shares. The firm’s market capitalization is $64.62 million. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10. The stock has a 50 day moving average of $3.47 and a 200 day moving average of $3.12.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.54. The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. Dicerna Pharmaceuticals’s quarterly revenue was up 2400.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.75) EPS. On average, equities research analysts predict that Dicerna Pharmaceuticals will post ($2.39) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “[[title]]” was originally published by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at [[permalink]].
A number of hedge funds have recently bought and sold shares of DRNA. Northern Trust Corp increased its stake in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 2,094 shares during the last quarter. Bourgeon Capital Management LLC boosted its stake in shares of Dicerna Pharmaceuticals by 188.9% in the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 25,500 shares during the period. Paloma Partners Management Co boosted its stake in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 53,131 shares during the period. Sabby Management LLC boosted its stake in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 100,000 shares during the period. Finally, UBS Group AG boosted its position in Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,599 shares during the period. Institutional investors and hedge funds own 56.05% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
To view ValuEngine’s full report, visit ValuEngine’s official website.